Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 370

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 370
---
2006. He has also been involved with the
start-up of five companies, all of which are still trading and one of which has been AIM listed. He was VP of Technology Development
for GSK Pharmaceuticals from December 2005 to April 2007. He was awarded visiting Professorial Chair in Chemistry at Sussex University
from August 1999 to May 2007 and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities
and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. He holds a BSc Hons and PhD in Chemistry from
the University of Southampton. Dr. Tapolczay also completed his Post-Doctoral Experience in Organic Chemistry from the University of
Oxford. Dr. Tapolczay was selected to serve on our board of directors following the Business Combination based on his deep knowledge
of Conduit, his extensive experience in research and development of clinical assets, and his in-depth knowledge of the pharmaceutical
industry.

72

James
(“Jamie”) Bligh. Mr. Bligh has served as a member of our board of directors since September 2023, and also currently
serves as our Interim Chief Financial Officer. He was a co-founder of Conduit Pharmaceuticals Limited in 2019 and has served as a member
of its board of directors since its inception. From 2008 to 2019, Mr. Bligh worked closely with investment vehicle Corvus Capital Limited,
including as a Partner, where he led a number of reverse takeover transactions, stock market listings, initial public offerings, secondary
fundraisings, and merger transactions. Mr. Bligh’s prior transaction experience includes advising several special purpose acquisition
vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the
subsequent acquisition of Bermele by East Imperial Pte. Ltd., a global purveyor of ultra-premium beverages, in June 2019; the listing
of Leverett Plc, which subsequently acquired Nuformix Plc, a pharmaceutical development company targeting unmet medical needs in fibrosis
and oncology via drug repurposing; and Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer. Jamie previously served as
a director of Bermele Plc from June 2021 through February 2022; Mertz Plc from January 2021 through March 2022; and East Imperial Pte.
Ltd